Flutamide and bicalutamide, in a cases of cancer that do not respond to therapy, function as agonists to stimulate the excessive production of androgen receptors (AR), thereby facilitating the advancement of the disease (Kelly et al., 1997). The gene discussed is AR; the disease is cancer.